Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Anti-von Willebrand Factor Nanobody, Caplacizumab
(D11160)		[2] Caplacizumab,
Von Willebrand factor human		[1] Caplacizumab (D11160) 💬[1] VWF 💬[8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬[1] 64 💬
2Anti-von Willebrand Factor Nanobody, INN = Caplacizumab
(D11160)		[2] Caplacizumab,
Von Willebrand factor human		[1] Caplacizumab (D11160) 💬[1] VWF 💬[8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬[1] 64 💬
3CAPLACIZUMAB
(D11160)		[1] Caplacizumab[1] Caplacizumab (D11160) 💬[1] VWF 💬[8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬[1] 64 💬
4Caplacizumab (ALX-0081)
(D11160)		[1] Caplacizumab[1] Caplacizumab (D11160) 💬[1] VWF 💬[8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬[1] 64 💬
5Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081)
(D11160)		[2] Caplacizumab,
Von Willebrand factor human		[1] Caplacizumab (D11160) 💬[1] VWF 💬[8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬[1] 64 💬
6Caplacizumab (an anti-von Willebrand Factor Nanobody)
(D11160)		[2] Caplacizumab,
Von Willebrand factor human		[1] Caplacizumab (D11160) 💬[1] VWF 💬[8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬[1] 64 💬